The androgen receptor (AR) is even more widely expressed in breast cancer (BC) than estrogen receptor alpha (ER) or progesterone receptor (PR), yet we still understand relatively little about its role or its potential as a therapeutic taget in the main subtypes of BC (ER+, Her2+ and triple negative). Thus, the long-term goal of this proposal is to determine how AR interacts with other pathways in BC subtypes, particularly in tumors that exhibit de novo or acquired resistance to current therapies. The objective is to utiliz old and new generation anti-androgens with different modes of action to elucidate the unique roles of AR and identify cooperating pathways to target in combination with AR. The central hypothesis is that AR plays subtype-specific roles and cooperates in different ways with proteins/pathways that drive these three main subtypes. Preliminary data demonstrate that AR plays crucial, subtype-specific roles in BC. The following specific aims will test the central hypothesis:
Aim 1. Elucidate the mechanism of action by which AR affects ER activity. Our working hypothesis is that nuclear AR is essential for E2/ER-driven proliferation in ER+/AR+ BC.
Aim 2. Identify mechanisms by which AR affects Her2+ BC. Liganded AR upregulates Her3 in some Her2+ BC lines; however, in many others Her3 is not affected, yet anti-androgens still inhibit proliferation. Thus, our working hypothesis is that there are novel mechanisms of action whereby AR impacts Her2+BC.
Aim 3. Determine the mechanisms by which AR supports survival and maintains a tumor initiating population to facilitate metastasis of AR+ TNBC. Determining how AR functions in BC subtypes and identification of previously unknown targetable pathways with which AR interacts, will lead to novel therapeutic strategies. Our studies challenge the dogma that AR and androgens are protective in breast cancer. We propose that like ER, AR is an indicator of a more well-differentiated type of tumor; however, it can most certainly drive BC growth and progression, and therefore represents a logical therapeutic target. .

Public Health Relevance

The proposed research investigating the role of the androgen receptor (AR) in breast cancer (BC) is relevant to public health because it will provide fundamental knowledge regarding nuclear hormone receptor action in BC and apply that knowledge towards improving treatment of this disease and reducing mortality. Since AR is even more widely expressed than estrogen receptors in BC, knowledge regarding AR and overlapping proteins/pathways that intersect with the AR pathway in different subtypes of BC will lead to novel therapeutic strategies. Indeed, for a subset of triple negative BC, for which there is, to date, no targeted therapy, anti-androgens may serve as a much-needed targeted approach for this aggressive BC subtype.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA187733-01A1
Application #
8964804
Study Section
Molecular and Cellular Endocrinology Study Section (MCE)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2015-07-02
Project End
2020-06-30
Budget Start
2015-07-02
Budget End
2016-06-30
Support Year
1
Fiscal Year
2015
Total Cost
$355,706
Indirect Cost
$126,956
Name
University of Colorado Denver
Department
Pathology
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Christenson, Jessica L; Trepel, Jane B; Ali, Haythem Y et al. (2018) Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer. Horm Cancer 9:82-94
He, Licai; Du, Zhuanyun; Xiong, Xusheng et al. (2017) Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer. Sci Rep 7:14584
Gordon, Michael A; D'Amato, Nicholas C; Gu, Haihua et al. (2017) Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer. Mol Cancer Ther 16:1389-1400
Christenson, Jessica L; Butterfield, Kiel T; Spoelstra, Nicole S et al. (2017) MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. Horm Cancer 8:69-77
Wellberg, Elizabeth A; Checkley, L Allyson; Giles, Erin D et al. (2017) The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer. Horm Cancer 8:269-285
Barton, Valerie N; Christenson, Jessica L; Gordon, Michael A et al. (2017) Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer. Cancer Res 77:3455-3466
D'Amato, Nicholas C; Gordon, Michael A; Babbs, Beatrice et al. (2016) Cooperative Dynamics of AR and ER Activity in Breast Cancer. Mol Cancer Res 14:1054-1067
Barton, Valerie N; D'Amato, Nicholas C; Gordon, Michael A et al. (2015) Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther 14:769-78